this post was submitted on 02 Apr 2025
7 points (100.0% liked)

Politics

659 readers
146 users here now

For civil discussion of US politics. Be excellent to each other.

Rule 1: Posts have the following requirements:
▪️ Post articles about the US only

▪️ Title must match the article headline

▪️ Recent (Past 30 Days)

▪️ No Screenshots/links to other social media sites or link shorteners

Rule 2: Do not copy the entire article into your post. One or two small paragraphs are okay.

Rule 3: Articles based on opinion (unless clearly marked and from a serious publication-No Fox News or equal), misinformation or propaganda will be removed.

Rule 4: Keep it civil. It’s OK to say the subject of an article is behaving like a jerk. It’s not acceptable to say another user is a jerk. Cussing is fine.

Rule 5: Be excellent to each other. Posts or comments that are homophobic, transphobic, racist, sexist, ableist, will be removed.

Rule 6: Memes, spam, other low effort posting, reposts, advocating violence, off-topic, trolling, offensive, regarding the moderators or meta in content may be removed at any time.

Rule 7. No conjecture type posts (this could, might, may, etc.). Only factual. If the headline is wrong, clarify within the body.

USAfacts.org

The Alt-Right Playbook

Media owners, CEOs and/or board members

Video: Macklemore's new song critical of Trump and Musk is facing heavy censorship across major platforms.

founded 2 years ago
MODERATORS
 

The Supreme Court on Wednesday largely upheld the Food and Drug Administration’s denials of two companies’ applications to sell flavored liquids for use in e-cigarettes. In a unanimous ruling, the justices threw out a ruling by the conservative U.S. Court of Appeals for the 5th Circuit holding that the FDA had improperly pulled a “regulatory switcheroo” when it gave the companies instructions that they followed but then ignored those instructions and denied authorization while imposing new requirements. In a 46-page ruling by Justice Samuel Alito, the court sent the case back to the court of appeals so that it could take another look at one aspect of the dispute – specifically, whether it made a difference that the FDA had changed its position and failed to consider marketing plans that the companies had submitted as part of their applications.

no comments (yet)
sorted by: hot top controversial new old
there doesn't seem to be anything here